Inotrem is an advanced clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets TREM-1, to control unbalanced and dysregulated inflammatory responses.
Inotrem targets the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of the TREM-1 pathway.
Inotrem has 2 late-stage clinical programs ongoing in acute inflammatory diseases such as septic shock and COVID-19 with its lead product nangibotide. Inotrem also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.
Inotrem targets the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of the TREM-1 pathway
Inotrem has 2 late-stage clinical programs ongoing in acute inflammatory diseases such as septic shock and COVID-19 with its lead product nangibotide. Inotrem also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.
Paris (France), January 9th. 2023. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under
Paris (France), January 9th. 2023. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2022 – Legal notices
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2022- Legal notices